Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07143448
PHASE1
A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults
Sponsor: 35Pharma Inc
View on ClinicalTrials.gov
Summary
Phase 1b Study of HS235 Assessing the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of the Activin Signaling Inhibitor HS235 Added to Background Treatment in Adults with Pulmonary Arterial Hypertension (PAH)
Official title: Phase Ib, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Assessing the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HS235 Added to Background Treatment in Adults With PAH
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2025-10
Completion Date
2028-01
Last Updated
2025-08-27
Healthy Volunteers
No
Conditions
Interventions
BIOLOGICAL
HS235
Subcutaneous Injection
OTHER
Placebo
Subcutaneous Injection